Madrigal Pharmaceuticals (MDGL) Operating Expenses (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Operating Expenses for 17 consecutive years, with $420.6 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Operating Expenses rose 61.75% year-over-year to $420.6 million; the TTM figure through Jun 2026 stood at $1.6 billion (up 94.65% YoY), while the FY2025 annual figure was $1.3 billion, up 85.62% from the prior year.
• Operating Expenses advanced to $420.6 million in Q2 2026 per MDGL's latest filing, from $404.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $420.6 million in Q2 2026 and bottomed at $57.6 million in Q1 2022.
• Historically, Operating Expenses has averaged $190.8 million across 5 years, with a median of $161.2 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses increased 8.7% — and 2025, when it surged 124.81%.
• Madrigal Pharmaceuticals' Operating Expenses stood at $85.3 million in 2022, then surged by 37.37% to $117.2 million in 2023, then soared by 45.35% to $170.3 million in 2024, then surged by 123.52% to $380.7 million in 2025, then climbed by 10.47% to $420.6 million in 2026.
• Business Quant data shows MDGL's Operating Expenses at $420.6 million in Q2 2026, $404.1 million in Q1 2026, and $380.7 million in Q4 2025.